Adverse cutaneous reactions to chemotherapeutic drugs

Haynes, Dylan; Ortega‐Loayza, Alex G.

doi:10.1016/j.clindermatol.2020.06.007

Cited by 24 publications

(37 citation statements)

References 257 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…eruptive nevi, serpentine supravenous hyperpigmentation, flagellate or reticulate hyperpigmentation, melanonychia, and post‐inflammatory hyperpigmentation (associated with repeated trauma, toxic erythema of chemotherapy, etc.) 6,10,14 …”

Section: Chemotherapeutic Agentsmentioning

confidence: 99%

“…Progressive development of a diffuse brown/bronze hyperpigmentation, even in non-sun-exposed areas like palmar creases, has been also described with busulfan (busulfan tan). 8,10,15 Although the hyperpigmentation usually fades after completion of chemotherapy, resolution of the pigmentary alterations is a gradual process that can take months or years. These adverse events (AEs) are therefore a major concern for patients and need to be addressed through preventive photoprotective measures in individuals initiating therapy with potential photosensitizing agents 10 (see Section Management recommendations and initiatives).…”

Section: Diffuse or Localized Hyperpigmentationmentioning

confidence: 99%

“…eruptive nevi, serpentine supravenous hyperpigmentation, flagellate or reticulate hyperpigmentation, melanonychia, and post-inflammatory hyperpigmentation (associated with repeated trauma, toxic erythema of chemotherapy, etc.). 6,10,14 Although post-inflammatory hyperpigmentation following a phototoxic reaction induced by chemotherapeutic agents such as 5-FU, tegafur, vinblastine, dacarbazine, and doxorubicin can occur in some cases, 6 localized or more diffuse hyperpigmentation after UVA/UVB exposure can also develop progressively without an initial inflammatory phase. These lesions are most prevalent in areas regularly exposed to UVA and UVB light, notably the dorsal aspect of the hands (Fig.…”

Section: Diffuse or Localized Hyperpigmentationmentioning

confidence: 99%

See 2 more Smart Citations

Anticancer treatments and photosensitivity

Sibaud

2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

Drug‐induced photosensitivity is associated with a wide range of anticancer treatments, including conventional chemotherapeutic agents, targeted anticancer therapies, and immune checkpoint inhibitors. These dermatologic adverse events can have a major impact on the well‐being and quality of life of cancer patients, leading to dose modifications and interruption or discontinuation of anticancer treatments in severe cases. However, the heterogeneous nature of the photosensitive reactions induced by these agents, as well as the common concomitant use of other potentially photosensitizing drugs (antibiotics, voriconazole, nonsteroidal anti‐inflammatory drugs, etc.), can make the diagnosis and, therefore the prevention, of these adverse events particularly challenging. The aim of this review is to describe the most characteristic forms of photosensitivity observed in patients being treated with anticancer treatments, including phototoxicity and photoallergy, and other potentially photo‐induced manifestations such as UV recall, exaggerated sunburn reactions associated with treatment‐related vitiligo, drug‐induced cutaneous lupus erythematosus, and UV‐induced hyperpigmentation. We also discuss the photosensitive reactions recently reported with new‐generation targeted anticancer therapies and immune checkpoint inhibitors and highlight the importance of continued surveillance to identify photosensitizing agents, and of educating patients on the need for preventive UVA/UVB photoprotective measures.

show abstract

Section: Chemotherapeutic Agentsmentioning

confidence: 99%

Section: Diffuse or Localized Hyperpigmentationmentioning

confidence: 99%

Section: Diffuse or Localized Hyperpigmentationmentioning

confidence: 99%

See 1 more Smart Citation

Anticancer treatments and photosensitivity

Sibaud

2022

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Anagen effluvium can start within days after administration of cytotoxic chemotherapeutic agents, including antimicrotubule agents such as paclitaxel. 3 Cytotoxic agents inhibit the mitotic or metabolic activity of hair matrix keratinocytes, leading to hair follicle damage and apoptosis. 4 The scalp swelling that occurred after the second round of chemotherapy most likely represented the start of lipedema.…”

mentioning

confidence: 99%

“…Antiandrogen therapy, such as tamoxifen, may also have a role in patterned hair loss. 3 However, the temporal onset of symptoms after paclitaxel administration suggests that there was a connection between the follicular damage and lipedema.…”

mentioning

confidence: 99%

Reply to “Presentation, diagnosis, and management options of lipedematous alopecia”

2021

View full text Add to dashboard Cite

Erythema nodosum following treatment with dasatinib plus chemotherapy in a patient with myeloid blast phase of chronic myeloid leukemia

Kassem,

Alshurafa,

Elsabah

et al. 2023

Clinical Case Reports

View full text Add to dashboard Cite

Key Clinical MessageErythema nodosum (EN) is a type of panniculitis occurring due to various conditions. It can be associated with certain malignancies or manifest as a side effect of drugs. This article presents a unique case of EN in a patient with chronic myeloid leukemia (CML‐blast phase) following dasatinib and chemotherapy. Timely recognition and appropriate management are crucial to alleviate symptoms and consider potential drug‐induced etiology.

show abstract

Adverse cutaneous reactions to chemotherapeutic drugs

Cited by 24 publications

References 257 publications

Anticancer treatments and photosensitivity

Anticancer treatments and photosensitivity

Reply to “Presentation, diagnosis, and management options of lipedematous alopecia”

Erythema nodosum following treatment with dasatinib plus chemotherapy in a patient with myeloid blast phase of chronic myeloid leukemia

Contact Info

Product

Resources

About